\nOnline Courses: Contact us at seminars@crossfit.com \nCrossFit Games Support: Reach out to support@crossfitgames.com \nFor T-Shirt Purchase: Check your inbox for instructions from customer@trackorder.site
\n","orderHistoryHeadlineText":"Order History","orderHistoryLabelText":"Order History","viewOrderDetailsText":"View order details"},"resourcesKickerText":"Resources","rulebookLabelText":"Rulebook","rulebookLinkUrl":"https://games.crossfit.com/rules","preferenceCenter":{"checkAllText":"Check All","emailCommunicationBodyText":"Select which lists you would like to receive communication from","emailCommunicationHeadlineText":"Email Communication","newsletters":[{"bodyText":"Every day since 2001, CrossFit has published a Workout of the Day for new CrossFit athletes, seasoned veterans, and anyone in between. Subscribe to Workout of the Day emails, and you'll receive CrossFit programming in a three-days-on, one-day-off, two-days-on, one-day-off cadence.","brazeGroupId":"d68551b9-ac7e-437e-bfd2-d225702413cc","headlineText":"Workout of the Day"},{"bodyText":"Get inspired with the latest and/or trending articles, stories, videos, and podcasts focused on the CrossFit community and methodology.","brazeGroupId":"1bfd806e-efe3-404d-9980-c8f38c39490b","headlineText":"What's Trending"},{"bodyText":"Be the first to know when official updates and announcements are released from CrossFit HQ.","brazeGroupId":"cb28cb07-ca09-4739-b73b-7413f95a4892","headlineText":"Updates and Announcements from CrossFit HQ"},{"bodyText":"This subscription is for those interested in announcements, updates, and stories about the CrossFit Games season and its competitors. ","brazeGroupId":"e56abfcc-c940-482d-879c-eed93958cbbe","headlineText":"CrossFit Games"},{"bodyText":"This monthly newsletter includes important CrossFit Games competition season updates, resources, and tips. It is intended for competitive athletes but is open to anyone interested in learning more about the CrossFit Games season.","brazeGroupId":"fce49890-9b3c-4e1f-9e06-1bd06cd696a3","headlineText":"The Hopper"},{"bodyText":"The Professional Coach provides a wealth of articles, media, and webinar opportunities that cover all aspects of coaching, including best practices, real-world coaching application, scaling, methodology, nutrition, CEU opportunities, and more. With contributions from experts inside and outside the CrossFit space, this twice-monthly newsletter is the ultimate tool for any coach looking to improve their skills and knowledge. This newsletter is exclusively available to those who hold a Level 1 Certificate or higher. ","brazeGroupId":"653207fb-9734-44c9-a988-23eb18142529","headlineText":"The Professional Coach"},{"bodyText":"The Affiliate Update is a newsletter for CrossFit affiliate owners and includes upcoming event details, business and marketing resources, and general updates from CrossFit HQ. The Affiliate Update is only available to licensees of record (LOR).","brazeGroupId":"1d3e4c63-f03f-4b61-8453-1fbb186ae27e","headlineText":"CrossFit Affiliate Update"},{"bodyText":"An email series for learning what it takes to open and run a successful CrossFit gym","brazeGroupId":"6ab8a53a-167c-4c74-b5ea-3a06cb857068","headlineText":"Interested in Affiliation"},{"bodyText":"CAP is a weekly email available exclusively to affiliate owners that provides comprehensive class plans, resources, and educational tips to help coaches deliver an exceptional experience to their members.","brazeGroupId":"ba7e977e-ec76-41e3-8465-158d38167ed6","headlineText":"CrossFit Affiliate Programming (CAP)"},{"bodyText":"CrossFit Health serves as a vital bridge connecting the realms of fitness and healthcare. Committed to delivering valuable insights, CrossFit Health harnesses the expertise of renowned professionals from the health, wellness, and CrossFit communities. Our mission is to educate individuals on the transformative potential of CrossFit as a powerful lifestyle intervention, ultimately optimizing health outcomes.","brazeGroupId":"a9c5a8a4-df0a-4b0c-acb6-e9b4631fc00c","headlineText":"CrossFit Health"},{"bodyText":"Be the first to know when new products are added to the Official CrossFit Store and receive special offers and discounts conveniently delivered directly to your inbox.","brazeGroupId":"905db0be-a3c8-4f5b-8903-536a04cb0a40","headlineText":"The CrossFit Store"},{"bodyText":"This subscription is for companies interested in on-site event activations and vendor booths at the CrossFit Games and other events hosted by CrossFit.","brazeGroupId":"92fa7fe8-262a-4d6a-9b0d-9fcc8cc17e7d","headlineText":"Interested in On-Site Event Activations / Vendor Booths"},{"bodyText":"Get alerted for upcoming courses. CrossFit courses and certifications are open to individuals and trainers seeking to improve their health and fitness through effective training and nutritional strategies.","brazeGroupId":"dd1ee7a4-2ef5-477b-affb-77347ce81684","headlineText":"Interested in Finding a Course Near You"}],"preferenceCenterHeadlineText":"Newsletter Preferences","preferenceCenterLabelText":"Newsletter Preferences","uncheckAllText":"Uncheck All"}}},"pages":{"breadcrumbs":{"links":[{"text":"Health","url":"/health"},{"text":"The WHO Trial","url":"#"}]},"contentPublishDate":"20190327","contentType":"article","commentTopics":[{"title":"The WHO Trial","topicId":"article.20190321135625226"}],"title":"The WHO Trial","topicId":"article.20190321135625226","socialMetaData":{"title":"The WHO Trial","image":"https://www.crossfit.com/wp-content/uploads/2019/03/27160326/Fig5-front.png"},"path":"/health/the-who-trial","components":[{"name":"ArticleHeader","props":{"topicId":"article.20190321135625226","date":"20190327","articleDate":"20190327","authorName":"CrossFit","bylineText":"By","headlineText":"The WHO Trial "}},{"name":"TextBlock","props":{"children":"
Scientists in Edinburgh, Budapest, and Prague began a study in 1965 to explore the potential of clofibrate, a cholesterol-lowering agent, to reduce ischaemic heart disease (heart attacks). The committee of principal investigators who shared the study’s findings in 1978 explained that in the years preceding the trial, “the association of raised serum lipids, particularly cholesterol, with an increased risk of developing ischaemic heart disease, was well established (e.g. Kannel et al., 1964).” They continue:
\n
Whether raised serum cholesterol actually was causative or, simply, the indication of an underlying metabolic disorder was not known. But on general principles, medical opinion held that it was desirable to reduce serum lipids towards accepted normal levels as far as possible. The means of achieving this were largely based on alterations in diet, and experience at that time suggested that the measures thought necessary were impracticable on any wide scale and were unlikely to be adhered to by most individuals in an affluent society. The possibility of using a cholesterol-lowering drug had been considered but until ethyl chlorophenoxyisobutyrate (later called clofibrate) was introduced (Oliver, 1962; Thorp, 1962; Thorp and Waring, 1962; Symposium on Atromid, 1963) none available satisfied the prerequisites of effectiveness and safety. Clofibrate was known to be capable of reducing plasma concentrations of low density, and very low density, lipoproteins, and thus cholesterol and triglyceride. It was decided, therefore, to initiate a trial in healthy volunteers to find out whether reducing plasma lipids, using clofibrate, would result in a decreased incidence of ischaemic heart disease. No deliberate attempt would be made to change the life style of participants or to rectify other risk factors.
\n
To test clofribrate’s effectiveness in reducing ischaemic heart disease, 5,000 men with cholesterol levels in the top third of the potential test population were given clofibrate (1.6 g/d). These men were compared to 5,000 men who had similar cholesterol levels and were given a placebo, and another 5,000 with cholesterol levels in the bottom third who also were given a placebo. This third group was designed to compare the effects of having “naturally” low cholesterol to the effects of having cholesterol levels pharmaceutically lowered. Subjects were followed for an average of 5.3 years. The primary outcome under consideration was major ischaemic heart disease (IHD): any fatal or nonfatal heart attack. Investigators expected clofibrate to reduce cholesterol levels by 15% and heart disease rates by 30%.
\n
Throughout the study, drug adherence was assessed to be relatively high; more than 94% of the subjects consistently took their prescription across all three sites. Two-thirds of the subjects completed the five-year intervention, with no visible differences between groups.
\n
Clofibrate successfully reduced the primary endpoint of major IHD, with 167 heart attacks observed in the treatment group and 208 in the high-cholesterol placebo group (See Table 3 below).¹
\n
From “A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate,” p. 1077
\n
Clofibrate also led to an average 9% decrease in cholesterol compared to the placebo (see Table 7 below). Both these decreases were slightly less than what investigators had anticipated, but remained statistically significant.
\n
From “A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate,” p. 1081
\n
It is also worth noting, particularly given the historical context, that this trial supported the significance of a variety of risk factors for heart disease, as high baseline serum cholesterol, high serum blood pressure, and cigarette smoking all had greater impacts on rates of heart disease than that reflected between the clofibrate and placebo groups (Table 9).
\n
From “A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate,” p. 1085
\n
The clofibrate group, however, experienced more fatal heart attacks than the placebo group (36 versus 34). There was a significant decrease in hypertension but no significant impact on angina pectoris, abnormal ECG, or cardiac arrhythmia.
\n
More importantly, clofibrate led to a significant increase in all-cause mortality compared to the placebo group. In the clofibrate group, 162 men died (age-adjusted rate: 4.9 deaths per 1,000 person-years) compared to 127 in the placebo (rate: 3.8). As noted above, there was no decrease in total cardiovascular mortality (54 versus 48 deaths), but there was a significant increase in all causes of death other than heart disease.
\n
Cancer mortality did not differ significantly between groups. No individual causes of death were significantly greater in the treatment group than the placebo, though there were more deaths related to respiratory, liver, and genituourinary disease in the treatment group. There were also more withdrawals due to diabetes and weight gain in the treatment group.²
\n
Thus, despite technically meeting the primary endpoint and sparking a thorough investigation into potential explanations for the disappointing results, the authors concluded:
\n
The results of the trial confirm the basic hypothesis that reduction of high serum cholesterol levels, even in middle-age, can reduce the incidence of IHD. However, the fact that clofibrate increases the incidence of gall stones, and the possibility that it may have even more serious local pathological consequences, indicate that it cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.
\n
Nevertheless, clofibrate remained in use until 2002, though by that point its use had decreased dramatically given the increasing use of statins to lower cholesterol levels.³
\n
Uffe Ravnskov and David Diamond comment on the WHO trial (among many others) in Fat and Cholesterol Don’t Cause Heart Attacks, noting in broad conclusion:
\n
Despite the largely disappointing findings from 50 years of cholesterol lower[-ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.
\n"}},{"name":"Button","props":{"variant":"secondaryBlue","children":"Read \"A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate\"","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC483536/pdf/brheartj00224-0001.pdf"}},{"name":"TextBlock","props":{"children":"\n
Footnotes
\n\n
The low-cholesterol placebo fared even better, with only 62 heart attacks. Going forward, “placebo” will refer only to the high-cholesterol placebo group.
\n
The suggestion here that clofibrate may cause liver damage would be substantiated by later research (see footnote 3).
\n","hideText":"Hide","status":"active","type":"alert_banner","userCanHide":"no"},"header":{"desktopLinks":[{"below":[{"id":93961,"parent":"93960","target":"_self","text":"What is CrossFit?","url":"/what-is-crossfit"},{"id":93962,"parent":"93960","target":"_self","text":"Find a Gym","url":"/map"}],"id":93960,"parent":"0","target":"_self","text":"Getting Started","url":"/what-is-crossfit"},{"below":[{"id":93964,"parent":"93963","target":"_self","text":"About","url":"/education/about"},{"id":93966,"parent":"93963","target":"_self","text":"Level 1 Certificate Course","url":"/certificate-courses/level-1"},{"id":93965,"parent":"93963","target":"_self","text":"Explore All Courses","url":"/education/explore-courses"},{"id":109033,"parent":"93963","target":"_self","text":"Private Courses","url":"/private-course/"},{"id":109034,"parent":"93963","target":"_self","text":"Military Resources","url":"/army-ignited"},{"id":93967,"parent":"93963","target":"_self","text":"Coaching Resources","url":"/education/resources"}],"id":93963,"parent":"0","target":"_self","text":"Courses","url":"/education/about"},{"below":[{"id":95951,"parent":"93968","target":"_self","text":"Workout of the Day","url":"/wod"},{"id":93969,"parent":"93968","target":"_self","text":"Explore Workouts","url":"https://www.crossfit.com/workout"},{"id":101892,"parent":"93968","target":"_self","text":"Hero Workouts","url":"https://www.crossfit.com/heroes/"},{"id":93970,"parent":"93968","target":"_self","text":"Movements","url":"https://www.crossfit.com/crossfit-movements"}],"id":93968,"parent":"0","target":"_self","text":"Workouts","url":"https://www.crossfit.com/workout"},{"id":93971,"parent":"0","target":"_self","text":"Learn","url":"/media"},{"id":93972,"parent":"0","target":"_blank","text":"Games","url":"https://games.crossfit.com"},{"id":105467,"parent":"0","target":"_blank","text":"Store","url":"https://store.crossfit.com/?utm_source=owned&utm_medium=nav&utm_campaign=main"},{"id":106137,"parent":"0","target":"_self","text":"Open A Gym","url":"/open-crossfit-gym"}],"mobileLinks":[{"text":"Open a CrossFit Gym"},{"text":"Browse","links":[{"below":[{"id":93961,"parent":"93960","target":"_self","text":"What is CrossFit?","url":"/what-is-crossfit"},{"id":93962,"parent":"93960","target":"_self","text":"Find a Gym","url":"/map"}],"id":93960,"parent":"0","target":"_self","text":"Getting Started","url":"/what-is-crossfit"},{"below":[{"id":93964,"parent":"93963","target":"_self","text":"About","url":"/education/about"},{"id":93966,"parent":"93963","target":"_self","text":"Level 1 Certificate Course","url":"/certificate-courses/level-1"},{"id":93965,"parent":"93963","target":"_self","text":"Explore All Courses","url":"/education/explore-courses"},{"id":109033,"parent":"93963","target":"_self","text":"Private Courses","url":"/private-course/"},{"id":109034,"parent":"93963","target":"_self","text":"Military Resources","url":"/army-ignited"},{"id":93967,"parent":"93963","target":"_self","text":"Coaching Resources","url":"/education/resources"}],"id":93963,"parent":"0","target":"_self","text":"Courses","url":"/education/about"},{"below":[{"id":95951,"parent":"93968","target":"_self","text":"Workout of the Day","url":"/wod"},{"id":93969,"parent":"93968","target":"_self","text":"Explore Workouts","url":"https://www.crossfit.com/workout"},{"id":101892,"parent":"93968","target":"_self","text":"Hero Workouts","url":"https://www.crossfit.com/heroes/"},{"id":93970,"parent":"93968","target":"_self","text":"Movements","url":"https://www.crossfit.com/crossfit-movements"}],"id":93968,"parent":"0","target":"_self","text":"Workouts","url":"https://www.crossfit.com/workout"},{"id":93971,"parent":"0","target":"_self","text":"Learn","url":"/media"},{"id":93972,"parent":"0","target":"_blank","text":"Games","url":"https://games.crossfit.com"},{"id":105467,"parent":"0","target":"_blank","text":"Store","url":"https://store.crossfit.com/?utm_source=owned&utm_medium=nav&utm_campaign=main"},{"id":106137,"parent":"0","target":"_self","text":"Open A Gym","url":"/open-crossfit-gym"}]}],"brandLinks":[{"id":93974,"parent":"0","target":"_self","text":"Open a CrossFit Gym","url":"/open-crossfit-gym"}],"loggedInMenu":[{"id":72863,"parent":"0","target":"_self","text":"Manage Account","url":"https://www.crossfit.com/dashboard"},{"id":72864,"parent":"0","target":"_self","text":"Competition Dashboard","url":"https://games.crossfit.com/manage-competition/athlete"}]},"footer":{"mainLinks":[{"below":[{"id":9764,"parent":"511","target":"_self","text":"What Is CrossFit?","url":"/what-is-crossfit"},{"id":9765,"parent":"511","target":"_self","text":"Get Started","url":"/get-started"},{"id":45861,"parent":"511","target":"_self","text":"Workouts","url":"/workout/"},{"id":45862,"parent":"511","target":"_self","text":"Movements","url":"/essentials/movements"},{"id":1741,"parent":"511","target":"_self","text":"FAQ","url":"/faq"},{"id":90183,"parent":"511","target":"_self","text":"Help Center","url":"https://crossfit.my.site.com/Support/s/"},{"id":45103,"parent":"511","target":"_self","text":"Careers","url":"/careers/"}],"id":511,"parent":"0","target":"_self","text":"About CrossFit","url":"#"},{"below":[{"id":45864,"parent":"45863","target":"_self","text":"Courses Near You","url":"/courses-near-you/"},{"id":45865,"parent":"45863","target":"_self","text":"Certificate Courses","url":"/certificate-courses/"},{"id":45866,"parent":"45863","target":"_self","text":"Certifications","url":"/certifications/"},{"id":45868,"parent":"45863","target":"_self","text":"Online Courses","url":"https://www.crossfit.com/online-courses"}],"id":45863,"parent":"0","target":"_self","text":"Education","url":"#"},{"below":[{"id":45870,"parent":"45871","target":"_self","text":"Open a CrossFit Gym","url":"/open-crossfit-gym"},{"id":45884,"parent":"45871","target":"_self","text":"Field Leaders","url":"/field-leaders"},{"id":90935,"parent":"45871","target":"_self","text":"Global Mentor Program","url":"/global-mentor-program/"},{"id":93982,"parent":"45871","target":"_self","text":"Affiliate Portal","url":"https://affiliate.crossfit.com/tools/"}],"id":45871,"parent":"0","target":"_self","text":"Affiliates","url":"#"},{"below":[{"id":16638,"parent":"45875","target":"_self","text":"Find a Trainer","url":"https://trainerdirectory.crossfit.com/"},{"id":45876,"parent":"45875","target":"_self","text":"Scholarship Program","url":"/scholarship-program-inquiry"},{"id":45877,"parent":"45875","target":"_self","text":"Foundation","url":"/foundation"},{"id":104122,"parent":"45875","target":"_self","text":"CrossFit Medical Society","url":"https://www.crossfitmedicalsociety.com/"}],"id":45875,"parent":"0","target":"_self","text":"Community","url":"#"},{"below":[{"id":45881,"parent":"45879","target":"_self","text":"About the Games","url":"https://games.crossfit.com/"},{"id":45880,"parent":"45879","target":"_self","text":"Leaderboard","url":"https://games.crossfit.com/leaderboard/games/2022?division=2"},{"id":45882,"parent":"45879","target":"_self","text":"Schedule","url":"https://games.crossfit.com/games/schedule?_ga=2.142929340.802559833.1690817966-401013740.1685640771"},{"id":91727,"parent":"45879","target":"_self","text":"Workouts","url":"https://games.crossfit.com/workouts/games/2023"}],"id":45879,"parent":"0","target":"_self","text":"The CrossFit Games","url":"#"}],"brandLinks":[],"socialLinks":[{"id":66715,"parent":"0","target":"_self","text":"facebook","url":"https://www.facebook.com/crossfit"},{"id":66716,"parent":"0","target":"_self","text":"twitter","url":"https://twitter.com/CrossFit"},{"id":66717,"parent":"0","target":"_self","text":"instagram","url":"https://www.instagram.com/crossfit/"},{"id":66718,"parent":"0","target":"_self","text":"youtube","url":"https://www.youtube.com/channel/UCtcQ6TPwXAYgZ1Mcl3M1vng"}],"contactLinks":[{"id":531,"target":"_self","text":"Careers","url":"https://www.crossfit.com/jobs"},{"id":532,"target":"_self","text":"Contact Us","url":"https://www.crossfit.com/contact-us"}],"legalLinks":[{"id":533,"parent":"0","target":"_self","text":"Terms & Conditions","url":"https://www.crossfit.com/terms-and-conditions"},{"id":534,"parent":"0","target":"_self","text":"Privacy Policy","url":"https://www.crossfit.com/privacy-policy"},{"id":10717,"parent":"0","target":"_self","text":"Cookie Policy","url":"https://www.crossfit.com/cookie-policy"},{"id":57312,"parent":"0","target":"_self","text":"Disclaimer","url":"https://www.crossfit.com/disclaimer"},{"id":10883,"parent":"0","target":"_self","text":"Contact Us","url":"https://www.crossfit.com/contact-us"},{"id":45883,"parent":"0","target":"_self","text":"Report IP Theft","url":"https://www.crossfit.com/iptheft"}]},"locationPages":{"simpleTiles":{"cards":[{"bodyText":"CrossFit offers a results-based, community-driven approach to functional training that helps you build strength and improve your health—over your lifetime.","headlineText":"Functional Fitness for Everyday Life","icon":{"alt":"Lifting Icon","url":"https://www.crossfit.com/wp-content/uploads/2024/04/26123658/crossfit-icon-workout-barbell-overhead-press.svg"}},{"bodyText":"Stay motivated with our community of coaches and members, who support your goals through approachable group training classes, helping you stay accountable and excited for each session.","headlineText":"Community Support and Motivation","icon":{"alt":"Heart Icon","url":"https://www.crossfit.com/wp-content/uploads/2024/04/26123700/crossfit-icon-heart.svg"}},{"bodyText":"Coaches scale class workouts to your fitness level to help you achieve your strength building goals.","headlineText":"Tailored to Your Fitness Levels","icon":{"alt":"Graph Icon","url":"https://www.crossfit.com/wp-content/uploads/2024/04/26123649/crossfit-icon-levels.svg"}},{"bodyText":"CrossFit coaches are experienced and trained to provide well-rounded and personalized guidance to individuals with varying fitness levels and goals.","headlineText":"Industry Certified Coaches","icon":{"alt":"Certification Icon","url":"https://www.crossfit.com/wp-content/uploads/2024/04/26123656/crossfit-icon-check-badge.svg"}}],"headlineText":"Build Strength for a Fuller Life"},"gymFinderPromo":{"bodyText":"Contact CrossFit to start your fitness journey. We’ll connect you to the closest gym in your area.","headlineText":"Get Started today","image":{"alt":"Man Lifting Barbell","sizes":{"1536x1536":"https://www.crossfit.com/wp-content/uploads/2018/12/13135656/aa6daff2983e555e3688654515568d25-1-768x512-1.jpeg","1536x1536Height":512,"1536x1536Width":768,"2048x2048":"https://www.crossfit.com/wp-content/uploads/2018/12/13135656/aa6daff2983e555e3688654515568d25-1-768x512-1.jpeg","2048x2048Height":512,"2048x2048Width":768,"hero":"https://www.crossfit.com/wp-content/uploads/2018/12/13135656/aa6daff2983e555e3688654515568d25-1-768x512-1.jpeg","heroHeight":512,"heroWidth":768,"heroLarge":"https://www.crossfit.com/wp-content/uploads/2018/12/13135656/aa6daff2983e555e3688654515568d25-1-768x512-1.jpeg","heroLargeHeight":512,"heroLargeWidth":768,"large":"https://www.crossfit.com/wp-content/uploads/2018/12/13135656/aa6daff2983e555e3688654515568d25-1-768x512-1.jpeg","largeHeight":512,"largeWidth":768,"medium":"https://www.crossfit.com/wp-content/uploads/2018/12/13135656/aa6daff2983e555e3688654515568d25-1-768x512-1.jpeg","mediumHeight":512,"mediumWidth":768,"mediumLarge":"https://www.crossfit.com/wp-content/uploads/2018/12/13135656/aa6daff2983e555e3688654515568d25-1-768x512-1.jpeg","mediumLargeHeight":512,"mediumLargeWidth":768,"small":"https://www.crossfit.com/wp-content/uploads/2018/12/13135656/aa6daff2983e555e3688654515568d25-1-768x512-1-300x200.jpeg","smallHeight":200,"smallWidth":300,"thumbnail":"https://www.crossfit.com/wp-content/uploads/2018/12/13135656/aa6daff2983e555e3688654515568d25-1-768x512-1-150x150.jpeg","thumbnailHeight":150,"thumbnailWidth":150}},"links":[{"link":{"priority":"primary","text":"Find a Gym","url":"/map"}},{"link":{"priority":"secondary","text":"What Is CrossFit?","url":"/what-is-crossfit"}}]},"locationCourseCards":{"courseLinkText":"Register Now","findCourseLink":{"text":"Find More Courses","url":"https://www.crossfit.com/courses-near-you"},"headerText":"Courses Near You","seminarType":["level-one","level-two"]},"socialSharing":{"facebook":{"description":"Jump into CrossFit in [City Name]! Our certified coach led group training and fitness classes feature strength, conditioning, and functional workouts.","title":"CrossFit Gyms in [State] | Functional Fitness Classes & Group Training"}}}},"user":{},"coachCertifications":{}}
Scientists in Edinburgh, Budapest, and Prague began a study in 1965 to explore the potential of clofibrate, a cholesterol-lowering agent, to reduce ischaemic heart disease (heart attacks). The committee of principal investigators who shared the study’s findings in 1978 explained that in the years preceding the trial, “the association of raised serum lipids, particularly cholesterol, with an increased risk of developing ischaemic heart disease, was well established (e.g. Kannel et al., 1964).” They continue:
Whether raised serum cholesterol actually was causative or, simply, the indication of an underlying metabolic disorder was not known. But on general principles, medical opinion held that it was desirable to reduce serum lipids towards accepted normal levels as far as possible. The means of achieving this were largely based on alterations in diet, and experience at that time suggested that the measures thought necessary were impracticable on any wide scale and were unlikely to be adhered to by most individuals in an affluent society. The possibility of using a cholesterol-lowering drug had been considered but until ethyl chlorophenoxyisobutyrate (later called clofibrate) was introduced (Oliver, 1962; Thorp, 1962; Thorp and Waring, 1962; Symposium on Atromid, 1963) none available satisfied the prerequisites of effectiveness and safety. Clofibrate was known to be capable of reducing plasma concentrations of low density, and very low density, lipoproteins, and thus cholesterol and triglyceride. It was decided, therefore, to initiate a trial in healthy volunteers to find out whether reducing plasma lipids, using clofibrate, would result in a decreased incidence of ischaemic heart disease. No deliberate attempt would be made to change the life style of participants or to rectify other risk factors.
To test clofribrate’s effectiveness in reducing ischaemic heart disease, 5,000 men with cholesterol levels in the top third of the potential test population were given clofibrate (1.6 g/d). These men were compared to 5,000 men who had similar cholesterol levels and were given a placebo, and another 5,000 with cholesterol levels in the bottom third who also were given a placebo. This third group was designed to compare the effects of having “naturally” low cholesterol to the effects of having cholesterol levels pharmaceutically lowered. Subjects were followed for an average of 5.3 years. The primary outcome under consideration was major ischaemic heart disease (IHD): any fatal or nonfatal heart attack. Investigators expected clofibrate to reduce cholesterol levels by 15% and heart disease rates by 30%.
Throughout the study, drug adherence was assessed to be relatively high; more than 94% of the subjects consistently took their prescription across all three sites. Two-thirds of the subjects completed the five-year intervention, with no visible differences between groups.
Clofibrate successfully reduced the primary endpoint of major IHD, with 167 heart attacks observed in the treatment group and 208 in the high-cholesterol placebo group (See Table 3 below).¹
From “A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate,” p. 1077
Clofibrate also led to an average 9% decrease in cholesterol compared to the placebo (see Table 7 below). Both these decreases were slightly less than what investigators had anticipated, but remained statistically significant.
From “A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate,” p. 1081
It is also worth noting, particularly given the historical context, that this trial supported the significance of a variety of risk factors for heart disease, as high baseline serum cholesterol, high serum blood pressure, and cigarette smoking all had greater impacts on rates of heart disease than that reflected between the clofibrate and placebo groups (Table 9).
From “A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate,” p. 1085
The clofibrate group, however, experienced more fatal heart attacks than the placebo group (36 versus 34). There was a significant decrease in hypertension but no significant impact on angina pectoris, abnormal ECG, or cardiac arrhythmia.
More importantly, clofibrate led to a significant increase in all-cause mortality compared to the placebo group. In the clofibrate group, 162 men died (age-adjusted rate: 4.9 deaths per 1,000 person-years) compared to 127 in the placebo (rate: 3.8). As noted above, there was no decrease in total cardiovascular mortality (54 versus 48 deaths), but there was a significant increase in all causes of death other than heart disease.
Cancer mortality did not differ significantly between groups. No individual causes of death were significantly greater in the treatment group than the placebo, though there were more deaths related to respiratory, liver, and genituourinary disease in the treatment group. There were also more withdrawals due to diabetes and weight gain in the treatment group.²
Thus, despite technically meeting the primary endpoint and sparking a thorough investigation into potential explanations for the disappointing results, the authors concluded:
The results of the trial confirm the basic hypothesis that reduction of high serum cholesterol levels, even in middle-age, can reduce the incidence of IHD. However, the fact that clofibrate increases the incidence of gall stones, and the possibility that it may have even more serious local pathological consequences, indicate that it cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.
Nevertheless, clofibrate remained in use until 2002, though by that point its use had decreased dramatically given the increasing use of statins to lower cholesterol levels.³
Uffe Ravnskov and David Diamond comment on the WHO trial (among many others) in Fat and Cholesterol Don’t Cause Heart Attacks, noting in broad conclusion:
Despite the largely disappointing findings from 50 years of cholesterol lower[-ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.
The low-cholesterol placebo fared even better, with only 62 heart attacks. Going forward, “placebo” will refer only to the high-cholesterol placebo group.
The suggestion here that clofibrate may cause liver damage would be substantiated by later research (see footnote 3).
The WHO Trial